Current Alzheimer Research

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back Subscribe
Translate in Chinese
Research Article

Unveiling the Potential Role of Cathinone and Cathine Compounds in Alzheimer's Disease: Predictive Insights

Author(s): Mohammed S. Alkaf, Musa A. Said*orcid of author, Noura A. Algamdiorcid of author and Nadia S. Al-Kaffauthors OrcID

Volume 22, Issue 7, 2025

Published on: 01 August, 2025

Page: [510 - 521] Pages: 12

DOI: 10.2174/0115672050386584250718130948

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Introduction: Khat (Catha edulis (Vahl) Forssk. ex Endl.), a stimulant plant native to Africa and Asia, contains psychoactive compounds such as cathinone and cathine that affect the central nervous system. This study aims to investigate the potential neurotoxicological risks associated with these compounds, particularly focusing on their possible relationship with neurodegenerative disorders like Alzheimer's disease (AD). The primary objective was to evaluate the toxicity of khat's main compounds and examine their molecular interactions with Monoamine Oxidase A (MAO-A), an enzyme implicated in the pathology of AD.

Methods: The toxicological profiles of cathinone, cathine, amphetamine, and the AD medication Donepezil were assessed using the Protox-3 server, which predicted toxicity class, potential for liver damage, carcinogenicity, immunotoxicity, mutagenicity, and cytotoxicity. Molecular docking studies were conducted to analyse the binding interactions of these compounds with MAO-A (PDB ID: 2Z5X). Binding affinities and key interacting residues were identified. The steric effects of the ligands within the enzyme's binding site were quantified by calculating the buried volume (%VBur) using the centroid of centres method.

Results: Protox-3 classified cathine and amphetamine as Class 3 toxicants (moderate toxicity), while cathinone and Donepezil were assigned to Class 4 (lower toxicity). Cathinone also demonstrated a moderate probability (0.64) of carcinogenicity. Molecular docking revealed that khat compounds had an average binding affinity of -5.81 ± 0.27 kcal/mol, which was lower than that of amphetamine (-6.10 ± 0.27 kcal/mol) and Donepezil (-7.80 ± 0.38 kcal/mol). Buried volume analysis indicated that khat compounds and amphetamine were more deeply embedded in the MAO-A binding site, correlating with stronger binding affinity.

Discussion: The computational results suggest that khat compounds exhibit moderate neurotoxic potential and interact with MAO-A in a manner that could be relevant to AD pathology. Although the binding affinities are lower than those of Amphetamine and Donepezil, they point to possible molecular-level interactions significant for neurodegeneration. Steric hindrance, as quantified by %VBur, appeared to influence binding strength, highlighting the importance of molecular fit within the active site.

Conclusion: This study presents evidence of a potential molecular link between khat consumption and an increased risk of Alzheimer's disease. The findings underscore the necessity for further in vivo and epidemiological research, particularly in regions with high rates of khat use, to assess its long-term neurotoxic effects.

Keywords: Khat, Alzheimer's Disease, MAO-A Enzyme, cathinone, cathine, in-silico. *

[1]
Bedada W, de Andrés F, Engidawork E, Hussein J, LLerena A, Aklillu E. Effects of Khat (Catha edulis) use on catalytic activities of major drug-metabolizing cytochrome P450 enzymes and implication of pharmacogenetic variations. Sci Rep 2018; 8(1): 12726.
[http://dx.doi.org/10.1038/s41598-018-31191-1] [PMID: 30143732]
[2]
Young JT, Butt J, Hersi A, Tohow A, Mohamed DH. Khat dependence, use patterns, and health consequences in Australia: An exploratory study. J Stud Alcohol Drugs 2016; 77(2): 343-8.
[http://dx.doi.org/10.15288/jsad.2016.77.343] [PMID: 26997193]
[3]
Fiidow OA, Minhat HS, Zulkefli NAM, Ahmad N. A systematic review on risk factors for khat chewing among adolescents in the African continent and Arabian Peninsula. PLoS One 2022; 17(2): 0263372.
[http://dx.doi.org/10.1371/journal.pone.0263372] [PMID: 35113927]
[4]
Ingegneri M, Smeriglio E, Zebbiche Y, et al. The dark side of “smart drugs”: Cognitive enhancement vs clinical concerns. Toxics 2025; 13(4): 247.
[http://dx.doi.org/10.3390/toxics13040247] [PMID: 40278563]
[5]
Lopez A, Gil-Lievana E, Gutierrez R. Sex-specific effects of appetite suppressants and stereotypy in rats. BioRxiv 2025; 2025.02.12.637751.
[http://dx.doi.org/10.1101/2025.02.12.637751]
[6]
Graziani M, Milella MS, Nencini P. Khat chewing from the pharmacological point of view: An update. Subst Use Misuse 2008; 43(6): 762-83.
[http://dx.doi.org/10.1080/10826080701738992]
[7]
Numan N. The green leaf: Khat, world. J Med Sci 2012; 7: 210-23.
[http://dx.doi.org/10.5829/idosi.wjms.2012.7.4.63142]
[8]
François M, Takagi K, Legrand R, et al. Increased ghrelin but low ghrelin-reactive immunoglobulins in a rat model of methotrexate chemotherapy-induced anorexia. Front Nutr 2016; 3: 23.
[http://dx.doi.org/10.3389/fnut.2016.00023] [PMID: 27508207]
[9]
Al-Motarreb A, Baker K, Broadley KJ. Khat: Pharmacological and medical aspects and its social use in Yemen. Phytother Res 2002; 16(5): 403-13.
[http://dx.doi.org/10.1002/ptr.1106] [PMID: 12203257]
[10]
Welsch ME, Zhou J, Gao Y, et al. Discovery of potent and selective leads against Toxoplasma gondii dihydrofolate reductase via structure-based design. ACS Med Chem Lett 2016; 7(12): 1124-9.
[http://dx.doi.org/10.1021/acsmedchemlett.6b00328] [PMID: 27994750]
[11]
Nencini P, Ahmed AM, Anania C, Moscucci M, Paroli E. Prolonged analgesia induced by cathinone. The role of stress and opioid and nonopioid mechanisms. Pharmacology 1984; 29(5): 269-81.
[http://dx.doi.org/10.1159/000138023] [PMID: 6093160]
[12]
Gannon BM, Baumann MH, Walther D, et al. The abuse-related effects of pyrrolidine-containing cathinones are related to their potency and selectivity to inhibit the dopamine transporter. Neuropsychopharmacology 2018; 43(12): 2399-407.
[http://dx.doi.org/10.1038/s41386-018-0209-3] [PMID: 30305739]
[13]
Freund-Michel VC, Birrell MA, Patel HJ, Murray-Lyon IM, Belvisi MG. Modulation of cholinergic contractions of airway smooth muscle by cathinone: Potential beneficial effects in airway diseases. Eur Respir J 2008; 32(3): 579-84.
[http://dx.doi.org/10.1183/09031936.00162707] [PMID: 18757696]
[14]
Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Res 2018; 46(W1): W257-63.
[http://dx.doi.org/10.1093/nar/gky318] [PMID: 29718510]
[15]
Heilman KM, Nadeau SE. Emotional and neuropsychiatric disorders associated with Alzheimer's disease. Neurotherapeutics 2022; 19(1): 99-116.
[http://dx.doi.org/10.1007/s13311-021-01172-w]
[16]
Gabr MT, Ibrahim MM. Multitarget therapeutic strategies for Alzheimer’s disease. Neural Regen Res 2019; 14(3): 437-40.
[http://dx.doi.org/10.4103/1673-5374.245463] [PMID: 30539809]
[17]
Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat Med 2020; 26(3): 387-97.
[http://dx.doi.org/10.1038/s41591-020-0762-2] [PMID: 32123386]
[18]
Jain P, Chaney AM, Carlson ML, Jackson IM, Rao A, James ML. Neuroinflammation PET imaging: Current opinion and future directions. J Nucl Med 2020; 61(8): 1107-12.
[http://dx.doi.org/10.2967/jnumed.119.229443] [PMID: 32620705]
[19]
Zhang QY, Wang Q, Fu JX, et al. Multi targeted therapy for Alzheimer's disease by guanidinium-modified calixarene and cyclodextrin co-assembly loaded with insulin. ACS Nano 2024; 18(48): 33032-41.
[http://dx.doi.org/10.1021/acsnano.4c05693]
[20]
Pei J, Kumarasamy RV, Jayaraman S, Kanniappan GV, Long Q, Palanisamy CP. Quercetin-functionalized nanomaterials: Innovative therapeutic avenues for Alzheimer’s disease management. Ageing Res Rev 2025; 104: 102665.
[http://dx.doi.org/10.1016/j.arr.2025.102665] [PMID: 39824363]
[21]
Luo H, Xiang Y, Qu X, et al. Apelin-13 suppresses neuroinflammation against cognitive deficit in a streptozotocin-induced rat model of Alzheimer’s disease through activation of BDNF-TrkB signaling pathway. Front Pharmacol 2019; 10: 395.
[http://dx.doi.org/10.3389/fphar.2019.00395] [PMID: 31040784]
[22]
Li H, Tan Y, Cheng X, et al. Untargeted metabolomics analysis of the hippocampus and cerebral cortex identified the neuroprotective mechanisms of Bushen tiansui formula in an aβ25-35-induced rat model of Alzheimer’s disease. Front Pharmacol 2022; 13: 990307.
[http://dx.doi.org/10.3389/fphar.2022.990307] [PMID: 36339577]
[23]
Chmielewski J, Chmielewski J, Bąk-Badowska J, Wójtowicz B, Żeber-Dzikowska I. Intoxication with new drugs - an ongoing challenge for public health and education. J Elem 2025; 30: 23-36.
[http://dx.doi.org/10.5601/jelem.2024.29.3.3424]
[24]
Chen S, Zhou W, Lai M. Synthetic cathinones: Epidemiology, toxicity, potential for abuse, and current public health perspective. Brain Sci 2024; 14(4): 334.
[http://dx.doi.org/10.3390/brainsci14040334]
[25]
Rosello-Molina V, Aparisi AH, Blanes MS, et al. Synthetic cathinone (α-pyrrolidinohexanophenone): An emerging threat. Eur Psychiatry 2022; 65(S1): S470-0.
[http://dx.doi.org/10.1192/j.eurpsy.2022.1193]
[26]
Cortes-Flores H, Torrandell-Haro G, Brinton RD. Association between CNS-active drugs and risk of Alzheimer’s and age-related neurodegenerative diseases. Front Psychiatry 2024; 15: 1358568.
[http://dx.doi.org/10.3389/fpsyt.2024.1358568] [PMID: 38487578]
[27]
Tzeng NS, Liu YP. Amphetamine exposure and dementia – A hypothesis of the long term sequelae of cognitive enhancers based on opponent process theory. Med Hypotheses 2019; 132: 109327.
[http://dx.doi.org/10.1016/j.mehy.2019.109327] [PMID: 31421431]
[28]
Schaefer AJ, Ingman VM, Wheeler SE. SEQCROW : A ChimeraX bundle to facilitate quantum chemical applications to complex molecular systems. J Comput Chem 2021; 42(24): 1750-4.
[http://dx.doi.org/10.1002/jcc.26700] [PMID: 34109660]
[29]
Ingman VM, Schaefer AJ, Andreola LR, Wheeler SE. QChASM: Quantum chemistry automation and structure manipulation. Wiley Interdiscip Rev Comput Mol Sci 2021; 11(4): 1510.
[http://dx.doi.org/10.1002/wcms.1510]
[30]
Banerjee P, Kemmler E, Dunkel M, Preissner R. ProTox 3.0: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Res 2024; 52(W1): W513-20.
[http://dx.doi.org/10.1093/nar/gkae303] [PMID: 38647086]
[31]
Cheng F, Li W, Zhou Y, et al. admetSAR: A comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model 2012; 52(11): 3099-105.
[http://dx.doi.org/10.1021/ci300367a] [PMID: 23092397]
[32]
Alsedfy MY, Ebnalwaled AA, Moustafa M, Said AH. Investigating the binding affinity, molecular dynamics, and ADMET properties of curcumin-IONPs as a mucoadhesive bioavailable oral treatment for iron deficiency anemia. Sci Rep 2024; 14(1): 22027.
[http://dx.doi.org/10.1038/s41598-024-72577-8] [PMID: 39322646]
[33]
Asghari N, Saei AK, Cordani M, Nayeri Z, Moosavi MA. Drug repositioning identifies potential autophagy inhibitors for the LIR motif p62/SQSTM1 protein. Comput Biol Chem 2024; 113: 108235.
[http://dx.doi.org/10.1016/j.compbiolchem.2024.108235] [PMID: 39369612]
[34]
Disha IJ, Hasan R, Bhuia S, Ansari SA, Ansari IA, Islam MT. Anxiolytic efficacy of indirubin: In Vivo approach along with receptor binding profiling and molecular interaction with gabaergic pathways. ChemistryOpen 2025; 14(2): 202400290.
[http://dx.doi.org/10.1002/open.202400290] [PMID: 39460441]
[35]
Son SY, Ma J, Kondou Y, Yoshimura M, Yamashita E, Tsukihara T. Structure of human monoamine oxidase A at 2.2-A resolution: The control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci USA 2008; 105(15): 5739-44.
[http://dx.doi.org/10.1073/pnas.0710626105] [PMID: 18391214]
[36]
Safhi MM, Alam MF, Hussain S, et al. Cathinone, an active principle of Catha edulis, accelerates oxidative stress in the limbic area of swiss albino mice. J Ethnopharmacol 2014; 156: 102-6.
[http://dx.doi.org/10.1016/j.jep.2014.08.004] [PMID: 25153022]
[37]
Kawahara M, Kato-Negishi M. Link between aluminum and the pathogenesis of Alzheimer′s disease: The integration of the aluminum and amyloid cascade hypotheses. Int J Alzheimers Dis 2011; 2011(1): 276393.
[http://dx.doi.org/10.4061/2011/276393] [PMID: 21423554]
[38]
Goudie AJ. Comparative effects of cathinone and amphetamine on fixed-interval operant responding: A rate-dependency analysis. Pharmacol Biochem Behav 1985; 23(3): 355-65.
[http://dx.doi.org/10.1016/0091-3057(85)90006-1] [PMID: 4048231]
[39]
Tzeng NS, Chien WC, Chung CH, Chang HA, Kao YC, Liu YP. Association between amphetamine-related disorders and dementia-a nationwide cohort study in Taiwan. Ann Clin Transl Neurol 2020; 7(8): 1284-95.
[http://dx.doi.org/10.1002/acn3.51113] [PMID: 32608133]
[40]
Ohara A, Yamada F, Fukuda T, Suzuki N, Sumida K. Specific alteration of gene expression profile in rats by treatment with thyroid toxicants that inhibit thyroid hormone synthesis. J Appl Toxicol 2018; 38(12): 1529-37.
[http://dx.doi.org/10.1002/jat.3693] [PMID: 30047161]
[41]
Syed AU, Liang C, Patel KK, et al. Comparison of monoamine oxidase-a, aβ plaques, tau, and translocator protein levels in postmortem human Alzheimer's disease brain. Int J Mol Sci 2023; 24(13): 10808.
[http://dx.doi.org/10.3390/ijms241310808] [PMID: 37445985]
[42]
Naoi M, Maruyama W. Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection. Int Rev Neurobiol 2011; 100: 85-106.
[http://dx.doi.org/10.1016/B978-0-12-386467-3.00005-4]
[43]
Wong KY, Roy J, Fung ML, Heng BC, Zhang C, Lim LW. Relationships between mitochondrial dysfunction and neurotransmission failure in Alzheimer’s disease. Aging Dis 2020; 11(5): 1291-316.
[http://dx.doi.org/10.14336/AD.2019.1125] [PMID: 33014538]
[44]
Kennedy BP, Ziegler MG, Alford M, Hansen LA, Thal LJ, Masliah E. Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer’s disease. J Neural Transm 2003; 110(7): 789-801.
[http://dx.doi.org/10.1007/s00702-003-0828-6] [PMID: 12811639]
[45]
Baldinger-Melich P, Gryglewski G, Philippe C, et al. The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography. Brain Stimul 2019; 12(3): 714-23.
[http://dx.doi.org/10.1016/j.brs.2018.12.976] [PMID: 30635228]
[46]
Lam CS, Li JJ, Tipoe GL, Youdim MBH, Fung ML. Monoamine oxidase A upregulated by chronic intermittent hypoxia activates indoleamine 2,3-dioxygenase and neurodegeneration. PLoS One 2017; 12(6): 0177940.
[http://dx.doi.org/10.1371/journal.pone.0177940] [PMID: 28599322]
[47]
Lương K, Nguyễn LTH. The role of Beta-adrenergic receptor blockers in Alzheimer’s disease: Potential genetic and cellular signaling mechanisms. Am J Alzheimers Dis Other Demen 2013; 28(5): 427-39.
[http://dx.doi.org/10.1177/1533317513488924] [PMID: 23689075]
[48]
Tremblay P, Pituello F, Gruss P. Inhibition of floor plate differentiation by Pax3 : Evidence from ectopic expression in transgenic mice. Development 1996; 122(8): 2555-67.
[http://dx.doi.org/10.1242/dev.122.8.2555] [PMID: 8756299]
[49]
Ishioh M, Nozu T, Miyagishi S, et al. Brain histamine improves colonic hyperpermeability through the basal forebrain cholinergic neurons, adenosine A2B receptors and vagus nerve in rats. Biochem Pharmacol 2024; 224: 116201.
[http://dx.doi.org/10.1016/j.bcp.2024.116201] [PMID: 38608783]
[50]
Andersson R, Galter D, Papadia D, Fisahn A. Histamine induces KCNQ channel-dependent gamma oscillations in rat hippocampus via activation of the H1 receptor. Neuropharmacology 2017; 118: 13-25.
[http://dx.doi.org/10.1016/j.neuropharm.2017.03.003] [PMID: 28274820]
[51]
DeLano WL. PyMOL Reference Guide. San Carlos, CA, US: Delano Scientific 2004; pp. 1-68.
[52]
Gurung AB, Bhattacharjee A, Ali MA. Exploring the physicochemical profile and the binding patterns of selected novel anticancer Himalayan plant derived active compounds with macromolecular targets. Inform Med Unlocked 2016; 5: 1-14.
[http://dx.doi.org/10.1016/j.imu.2016.09.004]
[53]
Walker WH, Kearney EB, Seng RL, Singer TP. The covalently-bound flavin of hepatic monoamine oxidase. 2. Identification and properties of cysteinyl riboflavin. Eur J Biochem 1971; 24(2): 328-31.
[http://dx.doi.org/10.1111/j.1432-1033.1971.tb19690.x] [PMID: 4333602]
[54]
DalleDonne I, Milzani A, Colombo R. The tert-butyl hydroperoxide-induced oxidation of actin Cys-374 is coupled with structural changes in distant regions of the protein. Biochemistry 1999; 38(38): 12471-80.
[http://dx.doi.org/10.1021/bi990367k] [PMID: 10493817]
[55]
Geha RM, Chen K, Wouters J, Ooms F, Shih JC. Analysis of conserved active site residues in monoamine oxidase A and B and their three-dimensional molecular modeling. J Biol Chem 2002; 277(19): 17209-16.
[http://dx.doi.org/10.1074/jbc.M110920200] [PMID: 11861643]
[56]
Liu J, Zhao M, Song W, et al. An amine oxidase gene from mud crab, Scylla paramamosain, regulates the neurotransmitters serotonin and dopamine in vitro. PLoS One 2018; 13(9): 0204325.
[http://dx.doi.org/10.1371/journal.pone.0204325] [PMID: 30248122]
[57]
Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJE. The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc 2015; 10(6): 845-58.
[http://dx.doi.org/10.1038/nprot.2015.053] [PMID: 25950237]

Rights & Permissions Print Cite